Zymeworks Inc.

Zymeworks Inc.

ZYME · Nasdaq

Zymeworks Inc. (ZYME) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Zymeworks Inc. in 2026. The next earnings report is expected on November 10, 2026.

Earnings calendar

Next earnings date

10 Nov 2026

In 83 days

EPS estimate

2.03

Revenue estimate

206.4M

Past earnings

06 Aug 2026
EPS actual
-0.62 (-9.2%)
estimate -0.57
Revenue actual
4.6M (+20.3%)
estimate 3.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
-0.59 (-98.8%)
estimate -0.30
Revenue actual
2.4M (-90.1%)
estimate 24.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
02 Mar 2026
EPS actual
-0.55 (-19.3%)
estimate -0.46
Revenue actual
2.5M (-86.9%)
estimate 19.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Zymeworks Inc. missed consensus on EPS but beat on revenue in its latest report, with EPS of -$0.62 falling short of the -$0.5676 estimate and revenue of $4.59 million exceeding estimates by 20.3%. In the prior report both EPS and revenue came in below expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Exchange
Nasdaq
CEO
Kenneth H. Galbraith
Employees
299
IPO date
28 Apr 2017
ISIN
US98985Y1082
Website
zymeworks.com

Frequently asked questions

When does Zymeworks Inc. (ZYME) next report earnings?

Zymeworks Inc. (ZYME) is scheduled to report earnings on November 10, 2026.

What was Zymeworks Inc.'s most recent earnings date?

Zymeworks Inc. (ZYME) last reported earnings on August 6, 2026.

Where is Zymeworks Inc. stock listed?

Zymeworks Inc. (ZYME) is listed on Nasdaq.